四种平台间胰岛素样生长因子-1结果与解读的不一致性
该比较研究用110份血清标本在Siemens Immulite 2000 XPi、DiaSorin Liaison XL、IDS iSYS三种化学发光自动免疫分析和LC-MS/MS法上检测IGF-1。加权Deming回归显示平台间存在系统性差异,整体一致性差,且差异随IGF-1值增大而增大。结论认为IGF-1检测缺乏标准化,平台切换给垂体疾病患者的监测与治疗带来挑战。
要点
- 四种平台检测IGF-1存在显著系统性差异,整体一致性差。
- 与Liaison相比,Immulite约负偏36%,iSYS约负偏8%,LC-MS/MS约负偏17%。
- 平台间差异随IGF-1值增大而增大,切换平台需谨慎解读结果。
核心结论
- 不同平台间IGF-1检测存在广泛差异,IGF-1检测缺乏标准化给临床监测与治疗垂体疾病患者带来挑战。
- 平台切换时应考虑IGF-1检测差异的潜在影响。
研究设计与样本
- 比较研究,共分析110份血清标本。
- IGF-1在Siemens Immulite 2000 XPi、DiaSorin Liaison XL、IDS iSYS三种化学发光自动免疫分析和LC-MS/MS法上检测。
- 结果用加权Deming回归比较,偏倚用Bland-Altman法评估。
主要发现
- 加权Deming回归显示Immulite较Liaison约负偏36%(Immulite = 0.64 * DiaSorin + 2.95,r2 = 0.95)。
- iSYS较Liaison约负偏8%(iSYS = 0.92 * DiaSorin + 0.51,r2 = 0.97)。
- LC-MS/MS较Liaison约负偏17%(LC-MS/MS = 0.83 * DiaSorin-11.23,r2 = 0.93)。
- LC-MS/MS较Immulite约正偏34%(LC-MS/MS = 1.34 * Immulite-21.97,r2 = 0.96)。
- IDS iSYS较Immulite约正偏81%(IDS iSYS = 1.81 * Immulite-117.65,r2 = 0.83)。
关键数值与推荐
- Bland-Altman图显示Immulite对DiaSorin显著负偏,IDS iSYS对Immulite显著正偏。
- 平台间整体一致性差,反映系统性差异,且差异随IGF-1值增大而增大。
临床怎么用
- 临床监测IGF-1及治疗垂体疾病患者时,应关注所用检测平台及平台切换带来的结果差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Inconsistent Insulin-like Growth Factor 1 (IGF-1) measurements among different platforms have been observed. In this study, we compared the IGF-1 assay on four different platforms. METHODS: A total of 110 serum specimens were analyzed in this comparison study. IGF-1 was measured on the three different chemiluminescent automated immunoassay of Siemens Immulite 2000 XPi, DiaSorin Liaison XL, IDS iSYS and LC-MS/MS method. Results were compared with Weighted Deming regression. Bias was evaluated using the Bland-Altman method. RESULTS: Weighted Deming regression analysis showed approximately 36 % negative variation on Immulite, compared to Liaison (Immulite = 0.64 * DiaSorin + 2.95, r2 = 0.95); 8 % negative variation on iSYS, compared to Liaison (iSYS = 0.92 * DiaSorin + 0.51, r2 = 0.97); 17 % negative variation on LC-MS/MS, compared to Liaison (LC-MS/MS = 0.83 * DiaSorin-11.23, r2 = 0.93); 34 % positive variation on LC-MS/MS compared to Immulite (LC-MS/MS = 1.34 * Immulite-21.97, r2 = 0.96); 81 % positive variation on IDS iSYS compared to Immulite (IDS iSYS = 1.81 * Immulite-117.65, r2 = 0.83). The Bland-Altman plot showed a significant negative variation of Immulite versus DiaSorin and positive variation of IDS iSYS versus Immulite. Overall agreement between different platforms was poor, which reflected systematic difference. The variation between platforms increased as IGF-1 values increased. CONCLUSIONS: There are wide variations between different platforms for IGF-1 measurement. The lack of standardization in IGF-1 measurement creates a challenge for clinicians to monitor IGF-1 and treat patients with pituitary disorders, when switching from one platform to another. The potential impact of the variations in IGF-1 measurement between different platforms should be taken into consideration when managing patients.
引用
- Lee JKY, Cradic K, Singh RJ, et al. Discordance of insulin-like growth factor-1 results and interpretation on four different platforms. Clin Chim Acta. 2022. PMID: 36528048. doi:10.1016/j.cca.2022.11.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。